TII
8.12.2021 10:34:09 CET | Business Wire | Press release
The Secure Systems Research Centre (SSRC) at Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the launch of its first Reduced Instruction Set Computer (RISC-V) based drone flight controller that leverages the Centre’s own secure PX4 stack. The flight marks a milestone in SSRC’s path to making RISC-V based UAV systems a reality through this successful testing and validation of the RISC-V + the secure PX4 stack system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005440/en/
Earlier this year, the Centre became a strategic member of RISC-V International, a non-profit organisation controlled by its members, which directs the future development and drives the adoption of RISC-V free and open Instruction Set Architecture (ISA). SSRC is focused on building an RISC-V based secure flight computer system. Today’s milestone is a major signpost on this path, with the Centre using a commercially available RISC-V development platform to port the DroneCode PX4 open source software to RISC-V.
Dr. Ray O. Johnson, CEO of TII, said: “RISC-V’s ISA is revolutionising the world of computing systems, and TII is proud to build this capability into our growing collection of breakthrough solutions that are future-proofing our world – one step at a time. We are seeing the use cases for drones and similar autonomous systems now spanning multiple sectors from e-commerce to healthcare and communication to security. This achievement will further strengthen our credibility as a global research centre at the forefront of cutting-edge technology that is working to shape an enabled and more secure world.”
Dr. Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “We are putting TII on the world map as leaders in pioneering Zero Trust Drone System research through this effort. The DroneCode community is the leading open-source community of PX4 Autopilot and fight controller hardware code and specification, respectively. A significant part of the work in realising this project required the porting of NuttX real-time OS and PX4 flight controller software to the RISC-V platform. SSRC has already included some of the planned security improvements into its existing PX4 software stack, and we will continue to develop this software and contribute the modifications back to open source.”
He added: “Through this milestone, we intend to highlight our regional expertise in the research and development of security for Drone and Autonomous Systems, an area that is set to have an outsized impact in shaping the Smart Cities of the future - making them safer and also significantly accelerating the opportunities for new services.”
As a follow-up, SSRC will continue to improve the security and resilience of the open source PX4 flight control software stack and NuttX real-time OS in collaboration with open source community. Furthermore, the Centre has presented a roadmap that includes improving memory protection of NuttX OS and PX4, protecting data on the removable media and utilising commercially available Root-of-Trust components.
Jukka Laitinen, Drone Software Lead Engineer and Architect at the SSRC in TII and Technical Lead for Dronecode Security Special Interest Group also presented a talk on making the current drone platform better, more secure, and resilient at the PX4 Autopilot Development Summit in September 2021.
SSRC is on track to achieving the first TII custom flight controller hardware, with the initial prototypes of this hardware, using a commercial off-the-shelf RISC-V SoC, expected by Q1 2022. This will enable researchers and industry to replace existing commercial flight controllers with a TII secure flight controller.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005440/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
